

Geneesmiddelen waarvoor voorafgaand aan de behandeling een machtiging moet worden aangevraagd - 2023

<u>ATC</u>	<u>Geneesmiddelengroep</u>	<u>Geneesmiddelen</u>	<u>Indicatie</u> Indien onderstaand een indicatie is gevuld, hoeft u alleen bij deze indicatie de machtiging aan te vragen. Indien er geen indicatie is gevuld dan altijd, dus bij alle indicaties, een machtiging aanvragen.
L01EF	CDK4/6 remmer	Abemaciclib, palbociclib, ribociclib	
L02B	Antihormonen	Abirateron, apalutamide, enzalutamide, estramustine	
I04AB	TNF- alfa remmers	adalimumab, certolizumab pegol, etanercept, golimumab, infliximab	Uveitis, zeldzame aandoeningen
D02BB02	alfa-MSH analoga	afamelanotide	EPP
S01LA	Angiogeneseremmers	aflibercept, ranibizumab, brolucizumab	Macula aandoeningen
L01XX35	anagrelide/ overige oncolytica	anagrelide	hematologie (incl. kinderen)
L04AA36	Anti-CD20	ocrelizumab	
J04AK05	antimycobacteriele middelen	bedaquiline	
L01EX12, L01EX14	anti-NTRK	larotrectinib, entrectinib	
M09AX07	antisense-oligonucleotide	nusinersen	
B01AB02	Antitrombine 3	antitrombine III	
B01AX	antitrombotica	caplacizumab, defibrotide	
J05AX18, J05AB	antivirale middelen	letermovir, remdesivir	
L01XX27	arseentrioxide	arseentrioxide	
L04AA26	BAFF remmer	belimumab	
L01XX52	BCL-2 remmers	venetoclax	
M03AX01	botuline toxine	botuline toxine	

L01EE (MEK); L01EC(BRAF)	BRAF/MEK remmers	binimetinib, cobimetinib, dabrafenib, encorafenib, trametinib, vemurafenib
L04AA25	C5 remmer	eculizumab
L04AA34	CD52	alemtuzumab
R07AX	CFTR-regulator	Ivacaftor, ivacaftor met lumacaftor, ivacaftor met tezacaftor, ivacaftor met tezacaftor en elexacaftor
L01A, L01B, L01C, L01D, L01XD, L01XF, L01XX	Chemotherapie	aminolevulinezuur, amsacrine, asparaginase, azacitidine, bendamustine, bexaroteen, bleomycine, busulfan, cabazitaxel, capecitabine, chloorambucil, chloormethine, cisplatine, clofarabine, cyclofosfamide, cytarabine, decitabine, docetaxel, doxorubicine, epirubicine, eribuline, etoposide, fludarabine, gemcitabine, hydroxycarbamide, idarubicine, irinotecan, lomustine, melfalan, methylaminolevulinaat, mitomycine, mitotaan, mitoxantron, nelarabine, oxaliplatine, paclitaxel, panobinostat, pegaspargase, pemetrexed, pixantron, procarbazine, tegafur, temoporfine, temozolomide, teniposide, thiotepa, topotecan, trabectedine, tretionoïne, trifluridene, vinblastine, vincristine, vinorelbine,
L01XX70, L01XX71	Chimere Antigen Receptor (CAR) T-cel therapie	axicabtagene ciloleucel, tisagenlecleucel,
L04AA28	CTLA-4 remmer	belatacept
L03AX16	CXCR4-antagonisten	plerixafor
A16AX10	enzyme remmers	eliglustat

A16AB	enzymen	alglucosidase alfa, agalsidase alfa, agalsidase beta, asfotase alfa, cerliponase alfa, elosulfase alfa, galsulfase, idursulfase, imiglucerase, laronidase, sebelipase alfa, velaglucerase alfa	Agalsidase alfa kwaliteitsvragen; http://www.huisarts.be/attestnl/replagal.pdf
B02BD04	Factor IX	Factor IX	
B02BD02	Factor VIII	Factor VIII, susoctocog alfa, von willebrand factor, protrombinecomplex geactiveerd	
B02BD07	Factor XIII	Factor XIII	
G03G	Fertiliteitshormonen	gonadereline, combinatiepreparaten, corifollitropine alfa, follitropine alfa, follitropine beta, follitropine delta, menopauzegonadotrofine, urofollitropine	
M05BX05	FGF23 remmer	burosumab	
S01XA27	gentherapie	voretigeeen neparvovec, atidarsageen autotemsel, onasemnogene abeparvovec	
R03DX05	IgE remmer	omalizumab	neuspoliepen
L01XC	immuuntherapie	aflibercept, atezolizumab, avelumab, bevacizumab, blinatumomab, brentuximabvedotine, cemiplimab, cetuximab, daratumumab, dinutuximab beta, durvalumab, elotuxumab, gemtuzumab, ozogamicine, ipilimumab, isatuximab, mogamulizumab, monoklonale antilichamen, nivolumab, obinutuzumab, panitumumab, pembrolizumab, pertuzumab, polatuzumab, voretigeeen, ramucirumab, rituximab, talimogeeen, laherparepvec, trastuzumab, trastuzumab emtansine,	oncologie
L01AC	interleukineremmers	anakinra, benralizumab, brodalumab, canakinumab, dupilumab, guselkumab, ixekizumab, mepolizumab, reslizumab, risankizumab, sarilumab, secukinumab, siltuximab, tildrakizumab, tocilizumab, ustekinumab	maligniteiten, hematologie.

L04AA37, L04AA44, L04AA29, L04AA45	JAK remmers	baricitinib, filgotinib, tofacitinib, upadacitinib, abrocitinib	
M09AX02	kraakbeencellen	kraakbeencellen, autoloog.	
L03AX15	MDP derivaat	mifamurtide	
L04AX08	mesenchymale stamcellen	darvadstrocel	
L01EG	m-TOR remmers	everolimus, temsirolimus	
N07XX12	weesgeneesmiddel	Patisiran	
L01XK	PARP-remmers	niraparib, olaparib, rucaparib, talazoparib	
L01EM01	PI3K remmers	idelalisib	
L01XG	proteasoomremmer	bortezomib, carfilzomib, ixazomib	
L01EM03, L01EX14	proteïne kinase remmers	alpelisib, entrectinib, tucatinib	
V10XX	radiofarmaca	lutetium 177 LU Oxodotreotide, lutathera	
L01XJ01	SMO remmers	vismodegib	basaalcelcarcinoom
S01XA19	Stamcellen	Limbale stamcellen, autoloog	
L04AX02, L04AX06	thalidomide derivaten	lenalidomide, pomalidomide	
L01EB	TKI	Afatinib, acalabrutinib, alectinib, axitinib, bosutinib, brigatinib, cabozantinib, ceritinib, crizotinib, dacomitinib, dasatinib, erlotinib, gefinitib, gilteritinib, ibrutinib, imatinib, lapatinib, lenvatinib, lorlatinib, midostaurine, nilotinib, nintedanib, osimertinib, pazopanib, ponatinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tivozanib, vandetanib,	